Sequential mutations associated with adaptation of human cytomegalovirus to growth in cell culture by Dargan, Derrick J. et al.
Sequential mutations associated with adaptation of
human cytomegalovirus to growth in cell culture
Derrick J. Dargan,
1 Elaine Douglas,
1 Charles Cunningham,
1
Fiona Jamieson,
1 Richard J. Stanton,
2 Katarina Baluchova,
1
Brian P. McSharry,
23 Peter Tomasec,
2 Vincent C. Emery,
3
Elena Percivalle,
4 Antonella Sarasini,
4 Giuseppe Gerna,
4
Gavin W. G. Wilkinson
2 and Andrew J. Davison
1
Correspondence
Derrick J. Dargan
d.dargan@mrcvu.gla.ac.uk
1MRC Virology Unit, Institute of Virology, University of Glasgow, Church Street,
Glasgow G11 5JR, UK
2Department of Medical Microbiology, Tenovus Building, School of Medicine, Cardiff University,
Heath Park, Cardiff CF14 4XX, UK
3Centre for Virology, Division of Infection and Immunity, Royal Free and University College
Medical School, Rowland Hill Street, Hampstead, London NW3 2QG, UK
4Servizio di Virologia, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy
Received 8 December 2009
Accepted 8 February 2010
Mutations that occurred during adaptation of human cytomegalovirus to cell culture were
monitored by isolating four strains from clinical samples, passaging them in various cell types and
sequencing ten complete virus genomes from the final passages. Mutational dynamics were
assessed by targeted sequencing of intermediate passages and the original clinical samples.
Gene RL13 and the UL128 locus (UL128L, consisting of genes UL128, UL130 and UL131A)
mutated in all strains. Mutations in RL13 occurred in fibroblast, epithelial and endothelial cells,
whereas those in UL128L were limited to fibroblasts and detected later than those in RL13. In
addition, a region containing genes UL145, UL144, UL142, UL141 and UL140 mutated in three
strains. All strains exhibited numerous mutations in other regions of the genome, with a
preponderance in parts of the inverted repeats. An investigation was carried out on the kinetic
growth yields of viruses derived from selected passages that were predominantly non-mutated in
RL13 and UL128L (RL13
+UL128L
+), or that were largely mutated in RL13 (RL13
”UL128L
+)o r
both RL13 and UL128L (RL13
”UL128L
”). RL13
”UL128L
” viruses produced greater yields of
infectious progeny than RL13
”UL128L
+ viruses, and RL13
”UL128L
+ viruses produced greater
yields than RL13
+UL128L
+ viruses. These results suggest strongly that RL13 and UL128L exert
at least partially independent suppressive effects on growth in fibroblasts. As all isolates proved
genetically unstable in all cell types tested, caution is advised in choosing and monitoring strains
for experimental studies of vulnerable functions, particularly those involved in cell tropism, immune
evasion or growth temperance.
INTRODUCTION
Human cytomegalovirus (HCMV; species Human herpes-
virus 5) can infect most major organs and a wide range of
cell types (Bissinger et al., 2002; Plachter et al., 1996;
Sinzger et al., 1995, 2008a). This broad tropism is lost
during adaptation of the virus to fibroblasts in cell culture
(Hahn et al., 2004; Kahl et al., 2000; MacCormac &
Grundy, 1999; Revello et al., 2001; Sinzger et al., 1999;
Waldman et al., 1989, 1991). Adaptation to fibroblasts is
associated strongly with mutations in a region encompass-
ing three small genes at nt 176309–178146 in reference
strain Merlin (GenBank accession no. AY446894). These
genes are UL128, UL130 and UL131A, which together are
termed the UL128 locus (UL128L). The mutations are
predicted to ablate gene functions, and include nucleotide
substitutions that introduce in-frame translational ter-
mination codons or compromise splicing, small insertions
or deletions (indels) that introduce frameshifts into coding
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Wellcome Building, Trinity College, Dublin 2, Ireland.
The GenBank/EMBL/DDBJ accession numbers for the genome
sequences of HCMV strains AF1, U8, U11 and VR1814 are
GU179291, GU179288, GU179290 and GU179289, respectively.
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more genes.
UL128L was originally described as containing four
unspliced coding regions: UL128, UL129, UL130 and
UL131 (Chee et al., 1990). Redefinition based on compar-
ative genomics led instead to three genes: UL128 (three
exons), UL130 (unspliced) and UL131A (two exons)
(Davison et al., 2003a). This arrangement was confirmed
by transcript mapping (Akter et al., 2003; Hahn et al., 2004).
Each gene was predicted to encode a small protein that
transits through the secretory pathway (Akter et al., 2003;
Hahn et al., 2004). The UL128 protein has sequence
similarity to CC chemokines (Akter et al., 2003; Hahn et al.,
2004), and the UL130 protein contains a putative CX
chemokine fold (Novotny et al., 2001; Wyrwicz &
Rychlewski, 2007). The observation that virus passaged in
fibroblasts is usually mutated in only one of the UL128L
genes implies that the proteins act in concert (Akter et al.,
2003; Hahn et al., 2004), and the implication that this
function is detrimental to growth of HCMV in these cells
has found experimental support (Adler et al., 2006; Wang &
Shenk, 2005a). In contrast, all three genes are known to be
essential for growth of HCMV in endothelial cells (Hahn
et al., 2004) and dendritic cells (Gerna et al., 2005), and at
least one (UL131A) for growth in epithelial cells (Wang &
Shenk, 2005a). These observations are consistent with an
involvement of UL128L in cell tropism, specifically for
infection of non-fibroblast cells (Sinzger, 2008; Sinzger
et al., 2000). The UL128L proteins are present in virions
(Adler et al., 2006; Patrone et al., 2005; Wang & Shenk,
2005b), where they form a complex with virus glycoproteins
H and L (gH–gL), as an alternative to glycoprotein O (gO)
in the gH–gL–gO complex, for entry into non-fibroblast
cells via endocytosis and low pH-dependent fusion
(Ryckman et al., 2006, 2008b) or direct fusion with the
plasma membrane (Patrone et al., 2007). This key role for
the gH–gL–UL128L complex is supported by the obser-
vation that antibodies against any of the UL128L proteins
inhibited infection of endothelial and epithelial cells, but
not fibroblasts (Adler et al., 2006; Macagno et al., 2010;
Wang & Shenk, 2005b). Also, endogenous expression of the
gH–gL–UL128L complex rendered epithelial cells, but not
fibroblasts, refractory to infection by viruses in which
UL128L was intact, thus implying that specific receptors
may exist on non-fibroblast cells (Ryckman et al., 2008a).
Mutations in other regions of the genome have been
reported for strains passaged in fibroblasts, and most
appear to be sporadic. However, several mutations affect
members of the RL11 gene family, which has 14 related
members (RL5A, RL6, RL11, RL12, RL13, UL1, UL4, UL5,
UL6, UL7, UL8, UL9, UL10 and UL11), most of which are
predicted to encode class I membrane glycoproteins (Chee
et al., 1990; Davison et al., 2003b). Lesions take the form of
termination, frameshift or deletion mutations, and have
been identified in RL13 (nt 11189–12070 in reference
strain Merlin), RL5A, RL6 and UL9 (Cunningham et al.,
2010; Dolan et al., 2004).
The observations described above depend largely on
targeted regions in the genomes of various HCMV strains.
We set out to paint a full picture of what happens
dynamically to entire HCMV genomes when adapted from
clinical samples to cell culture. Our aim was to identify
patterns of mutation that occur during adaptation and to
assess whether HCMV is genetically more stable in non-
fibroblast than in fibroblast cells.
RESULTS
Genomes sequenced completely
As multiple HCMV strains are common in clinical
samples, 14 isolates were tested during isolation by PCR
amplification of hypervariable genes UL146 and UL139,
followed by sequencing the inserts in several plasmids
(Bradley et al., 2008). The epidemiologically distinct AF1,
U8 and U11 isolates (see Methods) were each found to
consist of a single strain and were chosen for further
passaging. The analysis was complemented by data from a
fourth isolate (VR1814; see Methods) that had been
passaged earlier. All sequence data obtained were fully in
accordance with the presence of a single, unique strain in
each isolate.
The strategy for adapting strains AF1, U8 and U11 to
growth in cell culture is outlined in Fig. 1. The strains were
isolated from clinical samples by using human fetal
foreskin fibroblasts (HFFF-2) grown in shell vials, followed
by expansion of the infected cells by a limited number
(four/five) of passages. Infectivity was transferred in a
single passage by co-culture of infected HFFF-2 cells with
hTERT-immortalized human retinal pigmented epithelial
(RPE-1) cells or primary human umbilical vein endothelial
cells (HUVECs). Cell-free virus, obtained by sonication of
the co-cultures, was then used to establish passage series in
epithelial and endothelial cells, and passaging in fibroblasts
was also continued. The strains were subjected weekly to
collateral passaging (CP) in the three cell types by co-
culture until at least passage 50 (p50), except that passaging
of strain U11 in endothelial cells failed at an early stage for
unknown reasons. Strain VR1814 was passaged by using
similar methods, but much more extensively: 60 times in
fibroblasts (isolation) followed by CP, attaining p214 in
fibroblasts and p199 in endothelial cells (Fig. 1). In the
fibroblast series, passage numbering started with the first
isolation passage after growth in shell vials. In the epithelial
and endothelial cell series, numbering started with the
initiation of CP. Passage descriptions were abbreviated
according to strain name, cell type (F, fibroblasts; R,
epithelial cells; E, endothelial cells) and passage number.
Thus, passage 35 of strain U8 in epithelial cells was denoted
U8Rp35.
At the termination of CP, the complete HCMV genomes in
the final passages were sequenced, yielding a total of ten
sequences: AF1Fp60, AF1Rp50 and AF1Ep50; U8Fp65,
D. J. Dargan and others
1536 Journal of General Virology 91U8Rp51 and U8Ep51; U11Fp63 and U11Rp52; and
VR1814Fp214 and VR1814Ep199.
Genomes sequenced partially
Two further passage series (II and III) of strain U11 were
carried out in fibroblasts, in addition to the original series
(I). Series II involved initiating CP with the virus isolated
previously during series I (p4), whereas series III com-
menced with reisolation of virus from the clinical sample.
RL13 and UL128L were sequenced from the final passages
of series II and III (p51 and p40, respectively).
Strain VR1814 is the parent of the bacterial artificial
chromosome (BAC) FIX-BAC, which was generated by
cloning a genome present at p46 in fibroblasts (Hahn et al.,
2002) and sequenced (Murphy et al., 2003). A virus
(RVFIX7) reconstituted from FIX-BAC that had been
passaged approximately five times in fibroblasts (Hahn
et al., 2002) was treated with anti-mycoplasma agents
during five further passages in fibroblasts. This virus
was then subjected to CP by 117 passages in fibroblasts
or 94 passages in endothelial cells to derive RVFIXFp117
and RVFIXEp94. Sequence data were derived for the
region containing RL1–UL20 (nt 1772–28092, which
includes RL13) for VR1814Fp22, VR1814Fp48, FIX-BAC,
RVFIXFp117 and RVFIXEp94, and for the region contain-
ing UL122–UL150 (nt 168563–194150, which includes
UL128L) for VR1814Fp48, FIX-BAC, RVFIXFp117 and
RVFIXEp94.
Identification of mutations
Mutations in a particular strain were identified from
differences between the genome sequences at the final
passages, whether or not they were predicted to affect gene
functions. The mutated and wild-type versions were
differentiated from each other in two ways: directly on
the basis of targeted data from earlier passages and the
clinical samples, and indirectly by reference to sequence
alignments for other HCMV strains. Most mutations
consisted of substitutions or indels, but several sizeable
deletions were also detected. Mutations that did not result
in differences between the final sequences, but that had
been present in the clinical sample or had arisen during
isolation, would not have been detected except where they
potentially ablated gene functions. Also, extensive deletions
or rearrangements present in a proportion of, but not all,
genomes might not have been detected. Inspection of
sequence traces facilitated the identification not only of
predominant mutations, but also of mutations represented
in a significant minority (.10%) of the HCMV genome
population. The dynamics by which mutations arose
were monitored by reference to targeted sequence or PCR
data from earlier passages or the clinical samples. The
approaches used did not permit the complete absence of a
particular sequence (mutant or wild-type) to be inferred.
The mutations detected in the four strains are summarized
in Tables 1–4. Mutations were detected at each stage: a few
in the clinical samples (not included in Tables 1–4, but
described below), some during isolation (e.g. the substi-
tution in UL72 at nt 106148 of strain AF1; Table 1), and
the majority during CP (e.g. the substitution in UL72 at
nt 105981 of strain AF1; Table 1). It is notable that events
seem to have moved at a slower pace in epithelial cells than
in fibroblasts or endothelial cells.
The HCMV genome has the structure ab-UL-b9a9c9-US-ca,
where UL and US denote long and short unique regions and
ba/b9a9 and ca/c9a9 indicate inverted repeats flanking the
unique regions. The region most prone to mutations was
the b/b9 inverted repeat, with a lower frequency in the
flanking regions of the a/a9 and c/c9 inverted repeats.
Owing to the locations of the PCR products utilized for
sequencing, mutations in separate copies of the inverted
repeats could be evaluated for the whole of b/b9 and a/a9
and the proximal part of c/c9, and were found to be
approximately equimolar. This observation is consistent
with recombination between the repeats during virus DNA
replication.
Strain AF1
RL13 mutants were detected in fibroblasts (nt 11460
and 11667; the same genome population), epithelial
cells (nt 11488–11489) and endothelial cells (nt 10984)
Fig. 1. Scheme for isolation of HCMV strains
from clinical samples in fibroblasts and CP in
fibroblast, epithelial and endothelial cells. The
passage number (p) at which CP commenced
and terminated is shown for each strain. The
final passage numbers for fibroblasts include
those involved in virus isolation, whereas those
for non-fibroblast cells do not. ND, Not done.
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occurred only in fibroblasts, and was first detected in a
later passage (p20) than that in RL13 (p15). Seven clustered
substitutions occurred in UL123 (nt 172215–173747; the
same genome population) in endothelial cells. The strain
AF1 genome in the clinical sample was mutated in two
genes: RL6 containing an in-frame translational termina-
tion codon due to a C to A substitution at nt 5936, and
UL9 containing a frameshift due to an additional A residue
at nt 17079.
Strain U8
RL13 mutants were detected in fibroblasts (nt 11924),
epithelial cells (nt 11269–11270) and endothelial cells
(nt 11890) (Table 2). Mutation of UL128L (UL131A;
Table 1. Mutations that occurred during passage of strain AF1, with the final passages being F (p60), R (p50) and E (p50)
Location* RegionD Sequenced Coding effect Dynamics§ Intermediate passages||
NFRE
10984 RL13 G G G A^ Termination 14/18 5 10 12 14 16
11460 RL13 C G^ C C Substitution 15/23 5 10 15 16 18 20
11488–11489 RL13 2 2 D” 2 Frameshift 30 10 20
11667 RL13 C T^ C C Termination 15/23 5 10 15 16 18 20
57436 UL44 [T] C5 T T Substitution 50 5 12 25
105981 UL72 C C C T^ Substitution 30/30 5 12
106148 UL72 G A+ A+ G Substitution 60 (F); 50 (R) None (F); none (R)
134792–134836 UL89 in [45] 45 D^ 45 None 30/40 10 20 30
172215 UL123 [C] CC T5 Substitution 50 10 20 30 40
172317 UL123 [C] CC T5 Substitution 50 None
172375 UL123 [C] CC T5 None 50 None
173346 UL123 [C] CC T5 Substitution 46 10 20 30 40 42
173351 UL123 [C] CC T5 Substitution 46 10 20 30 40 42
173582 UL123 [C] CC T5 Substitution 44 10 20 30 40 42
173747 UL123 in [C] CC T5 None 46 10 20 30 40
177046 UL130 C A^ C C Termination 20/23 10 12 14 15 16 18 20
194890/944 b9 C A+ C C None 60 None
194979/855 b9 C A5 C C None 60 None
195025/809 b9 G C+ G G None 60 None
195037/797 b9 CC C A5 None 50 None
195049/785 b9 TT G” G5 None 60 (R); 50 (E) None (R); none (E)
195053/781 b9 T G” T T None 60 None
195056/778 b9 G C” G G None 60 None
195058/776 b9 T G” T T None 60 None
195081/753 b9 C A” C C None 60 None
195143/691/235892 a9 G T+ G G None 60 None
196025/235010 c9 A C+ A A None 60 None
*Location (nt) in the genome sequence. Multiple locations relate to duplications (b/b9 and c/c9) or triplications (a/a9/a) in the inverted repeats.
DRegions affected by mutations are protein-coding or non-coding. The latter are located in the inverted repeats (a9/b9/c9) or introns (in) or are
intergenic (IG).
dN, Not passaged (clinical sample); F, passaged in fibroblast cells; R, passaged in epithelial cells; E, passaged in endothelial cells. The mutated
nucleotide at each location is shown in bold, followed by a sign indicating relative abundance in the final passage: ^, only the mutated nucleotide
was detected; +, the mutated nucleotide predominated over the wild-type nucleotide; 5, the mutated and wild-type nucleotides were present in
approximately equal amounts; 2, the mutated nucleotide was less abundant than the wild-type nucleotide. Where a deletion (D) occurred, the size
(nt) is specified for the wild-type sequence. Where an insertion occurred, the original nucleotide is specified for the wild-type sequence and is
followed by additional nucleotides (or replaced by the total number of nucleotides for larger insertions) for mutated sequences. Square brackets
indicate that the sequence was not determined directly, but indirectly by reference to sequence alignments for other HCMV strains. ND, Passaging
not done.
§A single passage no. is that at which the mutation was first detected; a second passage no. is that at which only the mutation was detected. Square
brackets (Table 4 only) indicate that the mutation detected in the E series was first detected during isolation in F cells.
||Passages analysed prior to that at which the mutation was first detected or that at which only the mutation was detected are listed. Later passages
were also analysed.
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detected in a later passage (p18) than that in RL13 (p16).
Four clustered substitutions occurred in fibroblasts in the
region containing UL142 and UL141 (nt 182822–184383;
the same genome population). Complex, unresolved
sequence heterogeneity (not included in Table 2) was
evident as various deletions in the region containing the
b–UL junction in fibroblasts and possibly also epithelial
and endothelial cells. No obvious mutations were identified
in the strain U8 clinical sample.
Strain U11
Strain U11 was passaged successfully only in fibroblast and
epithelial cells (Table 3, series I). An RL13 mutation
(nt 11378) was detected in both cell types. Mutation of
UL128L (UL128; nt 176252 and 176307–176311; different
genome populations) was detected in fibroblasts, and was
first detected in a later passage (p15) than that in RL13
(p8). The same mutations were also detected at low levels
in epithelial cells. Generation of the five concurrent
substitutions at nt 176307–176311 probably occurred in a
single event involving switches of replication polarity or
recombination in a hairpin (ACGCCGTCAAGAACGGCGT;
inverted repeat underlined). The strain U11 genome in the
clinical sample was mutated in a single gene (UL9) due to a
frameshifting 23 bp deletion near the 39 end (between
nt 17102 and 17103). Several examples of mutations present
in both final passages were detected, including those in RL13
and UL128, implying that they may have arisen during
isolation. The reason for the apparently faster rate of mutant
selection in strain U11 than in strains AF1 and U8 is not
known.
To investigate whether the mutations detected in both final
passages had been present in the clinical sample or had
originated during isolation, two additional passage series
were carried out in fibroblasts. In series II, in which CP was
initiated with the virus isolated during series I, three
mutations in RL13 were detected (different genome
populations) and one in UL128L (again, UL128). One of
Table 2. Mutations that occurred during passage of strain U8, with the final passages being F (p65), R (p51) and E (p51)
Location* RegionD Sequenced Coding effect Dynamics§ Intermediate passages||
NF R E
11269–11270 RL13 2 2 D” 2 Frameshift 40 30 36 38
11890 RL13 A A A AA^ Frameshift 16/51 10 14 16 20 21 22 30
11924 RL13 G A^ G G Termination 16/20 11 12 14 16 18
35813 UL29 [A] G5 A A Substitution 65 10 20 30 39 50
49479 UL36 [C] CCT+ Substitution 10 10
49959 UL36 [C] CC5 C C Frameshift 50 10 20 30 39
58564 UL45 [C] C A” C Substitution 40 20 30
100119 UL69 [C] T^ C C Substitution 20/65 10 20 30 39 50
106348 UL72 [G] GGA+ Substitution 30 10 20
146722 UL100 [G] T5 G G Substitution 65 10 20 30 39 50
146904 UL100 [C] CC T^ Substitution 39/50 10 20 30 39
149267 UL102 [T] TT C^ Substitution 30/50 10 20 30 40
178000 UL131A C A^ C C Termination 18/20 10 12 14 15 16 18
181584 UL145 C G5 C C Substitution 32 30
181906–182456 UL144 551 551 551 D^ Deletion 30/51 30
182822 UL144/UL142 IG C T5 C C None 32 30
183281 UL144/UL142 IG C T+ C C None 32 30
183294 UL142 C T+ C C Substitution 32 30
184383 UL141 C T+ C C Substitution 32 9 20 30
186935 UL139/UL138 IG [C] G5 C C None 39 10 20 30
194454/1113 b9 T G^ T T None 65/65 None
194666/901 b9 C A^ C C None 65/65 None
194676/891 b9 T G5 T T None 65 None
194677/890 b9 C A5 C C None 65 None
194690/877 b9 C A+ C C None 65 None
194749/818 b9 C A^ A5 C None 65/65 (F); 51 (R) None (F); none (R)
194774/793 b9 C A^ C C None 65/65 None
194792/775 b9 C A+ C C None 65 None
194874/693/
235647
a9 [G] C^ G G None 65/65 None
See Table 1 for footnotes.
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detected in series I. In series III, which commenced with
reisolation of virus from the clinical sample, two mutations
in RL13 were detected (different genome populations) and
one in UL128L (again, UL128), none corresponding to
mutations observed in series I and II. In a further
investigation, PCR products from the RL13 and UL128
regions were generated from the clinical sample. None of
the 48 plasmids generated from each product contained
any of the mutations detected in series I, II and III.
Strain VR1814
Compared with strains AF1, U8 and U11, strain VR1814
had been subjected to more extensive passaging during
isolation and CP (Fig. 1) and more mutations were
observed (Table 4). However, the analysis was limited in
that the clinical sample was not available, and it was
possible to differentiate the mutated and wild-type versions
of a particular sequence only indirectly, by reference to
sequence alignments for other HCMV strains.
RL13 mutants were present in both fibroblasts and
endothelial cells (nt 10999–12018 and 11775; different
genome populations), and these were first detected during
isolation (p48; Table 4). A frameshift-inducing mutation in
UL128L (UL131A; nt 177905) in fibroblasts was first
detected during CP (p95). In addition, non-synonymous
substitutions in UL128L (UL130) that left the coding region
intact were detected in fibroblasts (p48; nt 177250) and
endothelial cells (p199; nt 176856). Complex, unresolved
sequence heterogeneity (not included in Table 4) was
detected in the b/b9 and a/a9 inverted repeats. No obvious
mutations in theclinicalsample were inferred. FIX-BACand
derived viruses RVFIXFp117 and RVFIXEp94 contained one
Table 3. Mutations that occurred during passage of strain U11, with the final passages in series I being F (p63) and R (p52)
Location* RegionD Sequenced Coding effect Dynamics§ Intermediate passages||
NF R
Series I
11378 RL13 A AA^ AA^ Frameshift 8/9 (F); 30/52 (R) 4 6 7 8 (F); 25 28 30
33 35 37 39 40 (R)
83326 UL55 C T^ C Substitution 58/62 20 30 40 45 50 58 60 61
176252 UL128 C A5 A– Termination 15 (F); 20 (R) 5 8 10 (F); 10 (R)
176307–176311 UL128 CAAGA TCTTG5 TCTTG” Substitutions 15 (F); 37 (R) 5 8 10 (F); 10 20 25 35
(R)
184505 UL141 G GT5 GT” Frameshift 63 (F); 52 (R) None (F); none (R)
193985/735 b9 C A” C None 63 None
194097/623 b9 T G5 T None 63 None
194099/621 b9 C A” A5 None 63 (F); 52 (R) None (F); none (R)
194104/616 b9 C A” C None 63 None
194144/576 b9 T G+ G+ None 63 (F); 52 (R) None (F); none (R)
194192/528 b9 T G” T None 63 None
194216/504/234725 a9 T C5 C” None 63 (F); 52 (R) None (F); none (R)
194220/500/234721 a9 G T+ G None 63 None
194222/498/234719 a9 A G5 G+ None 63 (F); 52 (R) None (F); none (R)
194263/457/234678 a9 T A” A” None 63 (F); 52 (R) None (F); none (R)
194268/452/234673 a9 GG A” None 52 None
194795/234146 c9 G T5 G None 63 None
194829/234112 c9 C G+ G+ None 63 (F); 52 (R) None (F); none (R)
222612 US26 C C T+ Substitution 20 None
Series II, which started with virus isolated in series I and shows mutations that occurred in RL13 and UL128L, with the final passage being
F (p51)
10795 RL13 G T” ND Termination 20 None
10976–10977 RL13 2 D” ND Frameshift 20 None
11378 RL13 A AA” ND Frameshift 40 13
175795 UL128 C A^ ND Not spliced 13/20 5 13 15
Series III, which started with virus reisolation and shows mutations that occurred in RL13 and UL128L, with the final passage being F
(p40)
11232–11233 RL13 2 D” ND Frameshift 21 10
11484 RL13 1 D+ ND Frameshift 21 7 10
175739 UL128 G A^ ND Termination 30/40 7 10 15 21 25 30 33
See Table 1 for footnotes.
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(UL130) mutations (nt 177250).
Passages of strain VR1814 in fibroblasts were assessed for
endotheliotropism (p55, p154 and p214) and leukocyte
transfer (p22, p48, p55, p95, p121, p143, p154, p179, p194
and p214). Endotheliotropism was lost between p55 and
p154, and remained negative at p214. Leukocyte transfer
was lost between p95 (2000 positive cells per 2610
5
leukocytes) and p154 (no positive cells), with reductions
Table 4. Mutations that occurred during passage of strain VR1814, with the final passages being F (p214) and E (p199)
Location* RegionD Sequenced Coding effect Dynamics§ Intermediate passages||
NF E
10999–12108 RL13 UL1 [1110] D+ D+ Deletion 48 (F); [48] (E) 22 25 30 41 (F); none (E)
11775 RL13 [A] AA+ AA+ Frameshift 48 (F); [48] (E) 22 25 30 41 (F); none (E)
28163–30607 UL23 UL24 UL25 [2445] 2445 D+ Deletion 199 None
41424 UL32 [G] A^ G Substitution 214 None
51484 UL38 [G] G GG5 Frameshift 199 None
57447 UL44 [T] T C5 Substitution 199 None
73746 UL50 [C] C CGAG+ In-frame
insertion
199 None
82573 UL55 [C] A5 C Substitution 214 None
82890 UL55 [T] T C^ Substitution 199 None
85615 UL56 [C] C T+ Substitution 199 None
89021 UL57 [T] T C^ Substitution 199 None
94456–94470 OriLyt [15] 15 D^ None 199 None
94474 OriLyt [C] 111^ 111^ None 214/214 (F);
199/214 (E)
None (F); none (E)
139372 UL89 [C] G+ C Substitution 214 None
145063 UL98 [A] C^ C^ Substitution 214/214 (F);
199/214 (E)
None (F); none (E)
163725 UL112 [T] T TGGT+ In-frame
insertion
199 None
171135 UL122 [G] G A^ Substitution 199 None
176856 UL130 [G] G T^ Substitution 199 None
177250 UL130 [A] G^ A Substitution 48/48 22
177905 UL131A [T] TT^ T Frameshift 95/121 22 25 30 41 48 55 95
181943 UL145/UL144 IG [T] T TT+ None 199 None
182580–185752 UL142 UL141
UL140
[3173] D^ D^ Deletion 48/143 (F);
[48]/199 (E)
22 25 30 41 48 55 95 121
(F); none (E)
194218/1118 b9 [C] C A^ None 199 None
194225/1111 b9 [T] G” T None 214 None
194290/1046 b9 [C] C A+ None 199 None
194352/984 b9 [C] A” C None 214 None
194367/969 b9 [C] C A^ None 199 None
194389/947 b9 [C] A” A+ None 214 (F); 199 (E) None (F); none (E)
194498/838 b9 [C] C A^ None 199 None
194563/773 b9 [C] G” C None 214 None
195182/154/234767 a9 [T] G” G^ None 214 (F); 199 (E) None (F); none (E)
195286/50/234663 a9 [A] A C^ None 199 None
195477/234472 c9 [A] C5 C5 None 214 (F); 199 (E) None (F); none (E)
195488/234461 c9 [C] A” C None 214 None
195545/234404 c9 [G] T+ T^ None 214 (F); 199 (E) None (F); none (E)
195552/234397 c9 [A] C” C^ None 214 (F); 199 (E) None (F); none (E)
195703/234246 c9 (IRS1) [A] C^ C+ Substitution 214 (F); 199 (E) None (F); none (E)
195709–197642 IRS1 [1934] 1934 D^ Deletion 199 None
198925 US1/US2 IG [T] T C5 None 199 None
225998 US28 [T] T TTT+ Frameshift 199 None
230525 US34 [G] G GAG5 Frameshift 199 None
See Table 1 for footnotes.
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cells) and leukocyte transfer remaining negative at p214.
These findings are consistent with detection of the UL128L
(UL131A) mutation at p95 and its predominance at p121
(Table 4). Both RVFIXFp117 and RVFIXEp94 tested
positive for leukocyte transfer and endotheliotropism.
Growth properties
The passage series derived for strains AF1, U8 and U11
provided a means for obtaining virus stocks that were largely
non-mutated in RL13 and UL128L (RL13
+UL128L
+),
mutated in RL13 (RL13
2UL128L
+) or mutated in both
locations (RL13
2UL128L
2). The process of generating
stocks was protracted, taking approximately 2 weeks for
RL13
2UL128L
2 viruses, 8 weeks for RL13
2UL128L
+
viruses and 10 weeks for RL13
+UL128L
+ viruses. To
distinguish between the ability of cell-free virus in these
stocks to initiate infection and to form a plaque, titrations in
fibroblasts were either subjected to immunofluorescence
(IF) analysis or stained for plaque counting. Regardless
of strain, the ratio of the number of IF-positive cells to
that of plaques was of the order of 100 for RL13
+UL128L
+
viruses, 10 for RL13
2UL128L
+ viruses, and ,10 for
RL13
2UL128L
2 viruses.
Kinetic-yield experiments in fibroblasts (Fig. 2) showed
that the RL13
2UL128L
2 viruses produced .10-fold more
cell-released virus (CRV) than RL13
2UL128L
+ viruses,
which in turn produced .100-fold more CRV than
RL13
+UL128L
+ viruses. Indeed, no CRV was detected
from RL13
+UL128L
+ viruses. All viruses produced
measurable amounts of cell-associated virus (CAV) at
8 days post-infection (p.i.), and the relative order was the
same as that for CRV.
DISCUSSION
Isolation and passaging of strains
Strains AF1, U8 and U11 were isolated by a few passages in
fibroblasts, thus subjecting them to fibroblast-associated
selection pressures prior to CP. Indeed, mutations that
apparently arose at this stage were identified for each
strain, in particular strain U11. Isolation in fibroblasts was
necessary because repeated attempts to isolate strains AF1,
U8 and U11 directly in epithelial and endothelial cells were
unsuccessful. This failure is consistent with the far greater
ease with which HCMV may be isolated in fibroblasts than
in other cell types (Gerna et al., 2002b). This phenomenon
may be connected in part with the neutralizing activity of
antibodies against the UL128L proteins (Gerna et al.,
2008), which are potentially bound to virus particles in the
inoculum. Historically, strains in clinical samples have
been isolated by passage in fibroblasts and then transferred
to other cell types either by co-culture of infected
fibroblasts and target cells or by infection of target cells
with cell-free virus produced by disruption of fibroblast
cultures (Gerna et al., 2000, 2002b; MacCormac & Grundy,
1999; Sinzger et al., 1999; Waldman et al., 1991). We
utilized co-culture for CP, which would have applied less
selection in favour of virus release than passage of cell-free
virus.
Mutations in RL13 and UL128L
In strains AF1 and U8, RL13 mutated in fibroblast,
epithelial and endothelial cells (at a different location in
each cell type), and UL128L (UL130 and UL131A,
respectively) mutated only in fibroblasts. In strain U11,
for which endothelial-cell passaging failed, mutations in
RL13 and UL128L (UL128) were detected in both
fibroblasts and epithelial cells, indicating that they had
Fig. 2. Kinetics of virus growth in fibroblasts of RL13
+UL128L
+
(X), RL13
”UL128L
+ (&) and RL13
”UL128L
” (m) viruses
derived from strains AF1, U8 and U11. The connected points
show CRV titres and the unconnected points on the right show
CAV titres. Values below the limit of detection (dotted line) are
assigned to the x-axis.
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requirement for UL128L in non-fibroblast cells, the
UL128L mutations in strain U11 were predominant in
fibroblasts, but present at low levels in epithelial cells,
where they were presumably maintained by complementa-
tion. In strain VR1814, RL13 mutated during isolation, and
the UL128L (UL131A) mutant was detected later in
fibroblasts, but not endothelial cells. In all four strains,
mutation of RL13 in fibroblasts was detected before that of
UL128L, and mutations in both loci quickly became
predominant.
The loss of UL128L and RL13 fits with previous
observations on the presence of mutations in these loci
in strains passaged in fibroblasts. However, in contrast to
UL128L, RL13 mutated not only in fibroblasts, but also in
epithelial and endothelial cells. Moreover, kinetic-yield
experiments suggested that RL13 and UL128L suppress
growth in fibroblasts at least partially independently,
pointing to the involvement of different functional path-
ways. CP-derived viruses were used to investigate growth
properties, but were of limited utility because they
contained small amounts of alternative genotypes, and
other mutations were also present in various proportions.
Nonetheless, the similar growth properties obtained for
viruses derived from strains AF1, U8 and U11 support the
view that whether RL13 and UL128L were mutant or non-
mutant was the main factor affecting differences in growth
properties. In accord, a collaborative study has shown that
virus derived from a strain Merlin BAC containing the
wild-type gene complement (RL13
+UL128L
+) invariably
mutated in RL13 in both fibroblasts and epithelial cells,
with UL128L mutants being detected later only in
fibroblasts (R. J. Stanton, unpublished data). Future
investigations into the growth properties of RL13
+
UL128L
+ virus are likely to be made to best effect using
the Merlin system.
The number of passages required for RL13 and UL128L
(UL131A) to mutate in strain VR1814 appeared to be
greater than that for the other strains. The observations
that mutation of UL128L (UL131A) was detected at a
particularly late stage (p95) and that the FIX-BAC-derived
viruses (RVFIXFp117 and RVFIXEp94; both ostensibly
RL13
2UL128L
+) did not mutate during passage in
fibroblasts suggest genetic compensations elsewhere. In
this connection, it is notable that strain VR1814 grown
in fibroblasts had an additional, earlier mutation in
UL128L, specifically a non-synonymous substitution in
UL130. This mutation was inherited by FIX-BAC and the
viruses derived from it. It is possible that this mutation
reduced the selection pressure for further mutations in
UL128L during growth in fibroblasts, whilst permitting the
retention of a degree of endotheliotropism and ability to
transfer to leukocytes. This might explain why UL128L
mutations engineered into FIX-BAC-derived viruses did
not result in significantly enhanced growth in fibroblasts in
kinetic-yield experiments (Hahn et al., 2004; commented
on by Wang & Shenk, 2005a). In a similar vein, strain
TB40/E (Sinzger et al., 2008b) has a unique non-
synonymous substitution in UL130 that might account
for its ability to grow in both fibroblasts and endothelial
cells (Dolan et al., 2004). These comments prompt caution
about assuming wild-type status for UL128L in fibroblast-
passaged HCMV strains (as viruses or BACs) that retain
the ability to grow in non-fibroblast cells.
It is not fully understood why UL128L is detrimental to
growth in fibroblasts, although inhibition of virion release
has been proposed (Adler et al., 2006; Wang & Shenk,
2005a). Preliminary studies indicate that the RL13 product
is a 100 kDa type I transmembrane glycoprotein (K.
Baluchova, unpublished data), but its function and the
reason for its inhibitory properties are unknown. It is
possible that its suppressive effects in cell culture reflect
similar properties operating in vivo, where HCMV
persistence might be facilitated by mechanisms that temper
virus replication. Alternatively, the effect might result from
an interference with replication in cell culture that does not
occur in vivo. Nonetheless, there remains a striking contrast
between the enfeebled growth properties of RL13
+
UL128L
+ virus in cell culture and the ability of HCMV
to replicate well in clinical situations (Emery et al.,
1999).
Mutations in UL145–UL140
After passaging in endothelial cells, strain U8 had a
551 bp deletion in UL144 that also had the potential for
affecting UL145 transcription (Table 2). After passage in
fibroblasts and epithelial cells, strain U11 had a single
nucleotide insertion that caused a frameshift in UL141
(Table 3). After passage in fibroblasts and endothelial
cells, strain VR1814 had a 3173 bp deletion that affected
UL142, UL141 and UL140 and possibly also UL144
transcription (Table 4). Only strain AF1 was unaffected
in this region. Lesions usually took the form of
deletions, suggesting that more than one gene was
selected against, although not as strongly as RL13 and
UL128L.
Mutations in a region containing five genes (UL145,
UL144, UL142, UL141 and UL140) have been identified
for strain AD169 varUC in fibroblasts (ablating UL144,
UL142, UL141 and perhaps affecting UL140 transcrip-
tion), strain TB40/E in endothelial cells (UL141, with a
derivative additionally compromised in UL145 and
UL144) and strain VR3216B in endothelial cells (UL142)
(Bradley et al., 2009; Sinzger et al.,2 0 0 8 b ;T o m a s e cet al.,
2005; GenBank accession no. GQ222018). In addition, the
genomes of the most widely used HCMV strains, AD169
(varUK and varATCC) and Towne (varS), each lack a
sizeable region (UL/b9; 15 or 19 genes, respectively) that
includes UL145–UL140 (Bradley et al.,2 0 0 9 ;C h aet al.,
1996; Davison et al.,2 0 0 3 a ;M u r p h yet al.,2 0 0 3 ) .I ti s
possible that these extensive deletions represent one end
of a spectrum of mutations whose key effect is to disable
UL145–UL140.
HCMV genome adaptation
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All four strains exhibited numerous mutations in the
inverted-repeat regions. The dynamics by which these
mutations arose was not determined. Their frequent
occurrence might be promoted in part by recombination,
but other factors are probably important, as the major part
of c/c9 was not affected. Many of the mutations in other
regions of the genome were non-synonymous substitu-
tions, which suggests that at least some were selected
because they provided growth advantages. A cluster of
mutations in the same genome population was evident for
strains AF1 and U8, in UL123 for the former and in the
region of UL142 and UL141 for the latter. These clusters
may have resulted from local, error-prone replication of a
genome whose progeny was then selected.
Origins of mutations
The passaging experiments show that the HCMV genome
was unstable during adaptation to cell culture, regardless of
virus strain and cell type. However, the identification of
mutations that apparently arose during isolation raised the
question of whether they might have been present at low
levels in the clinical sample. This possibility is technically
difficult to rule out. If it is the case, the data from
reisolation of strain U11 indicate the existence of a swarm
of different mutants, each present at a very low level in the
clinical sample. However, there was no evidence from
sequence traces for the prior existence of any mutation.
Moreover, none of the RL13 or UL128 mutants in strain
U11 was detected in sets of PCR-derived plasmid clones
generated from the clinical sample, thus excluding an
approximate frequency per mutation of .2%.
In contrast to the lack of evidence for the presence of the
mutations described above in the clinical samples, a small
number of mutations (in RL6 and UL9) were identified as
characterizing the entire populations of HCMV genomes in
the clinical samples from which strains AF1 and U11 were
derived. Their identification strengthens the view that
HCMV mutants lacking functions, particularly in the RL11
gene family, exist in clinical settings (Cunningham et al.,
2010; Sekulin et al., 2007).
METHODS
Clinical samples. Clinical samples were obtained in accordance with
the relevant national ethical guidelines. Strains AF1, U8 and VR1814
originated from Pavia, Italy, and strain U11 from London, UK. Strain
AF1 was derived from amniotic fluid from a pregnant woman
infected with HCMV, strains U8 and U11 from urine from infants
infected congenitally with HCMV, and strain VR1814 from the
cervical secretions of a pregnant woman with a primary HCMV
infection.
Cell lines. Strains AF1, U8 and U11 were isolated and passaged in
Glasgow, UK, in three different cell lines (Fig. 1). HFFF-2 cells
(ECACC 86031405) were grown in Dulbecco’s modified Eagle’s
medium (DMEM)/10% (v/v) fetal calf serum. hTERT-immortalized
RPE-1 cells (Clontech C4000-1) were grown in DMEM/Ham’s F-12
supplement/10% (v/v) fetal calf serum. Primary HUVECs were
prepared from umbilical cords from consenting anonymous volun-
teers attending the Queen Mother’s Maternity Hospital, Glasgow, UK.
Cords were obtained in accordance with National Health Service
ethical guidelines. HUVECs were grown using the EGM-2 BulletKit
system (Lonza) without heparin and subjected to IF using mouse
antibody MCA 127T (Serotec) to confirm the presence of the von
Willebrand factor. Each cell line was checked regularly for
mycoplasma contamination by using a Minerva Biolabs VenorGeM
mycoplasma detection kit (Cambio). Strain VR1814 was isolated and
passaged similarly in Pavia, Italy, using human embryo lung
fibroblasts (VO cells) and primary HUVECs.
Isolation of HCMV strains. The AF1, U8 and U11 clinical samples
were diluted 1:3 with DMEM and 500 ml was inoculated onto
fibroblasts grown on glass coverslips in shell vials. Following
centrifugation at 450 g for 30 min at 18 uC, the cultures were
incubated overnight at 37 uC. The cultures were then trypsinized and
the infected cells were expanded by passaging, reaching the stage of
75 cm
2 cell-culture flasks. Plaques first appeared for strains AF1, U8
and U11 at p2, p4 and p2, respectively, and infectivity was transferred
to epithelial and endothelial cells by co-culture with infected
fibroblasts at p5, p5 and p4, respectively. Co-cultures were harvested
by scraping the cells into the medium and disrupting them by
ultrasonic treatment. Cell-free virus was then used to infect
fresh monolayers of epithelial and endothelial cells, thus avoiding
overgrowth by fibroblasts. Passaging in fibroblasts was also continued.
Strain VR1814 was isolated and transferred similarly, except that it
was passaged 60 times in fibroblasts (isolation) and then transferred
to endothelial cells or continued in fibroblasts for CP.
Passaging of HCMV strains. Strains AF1, U8 and U11 were
subjected to CP (.50 times) in fibroblast, epithelial and endothelial
cells on a weekly basis by co-culture of infected cells with uninfected
cells. Split ratios (infected:uninfected cells) depended on the extent
of cytopathic effect (CPE). Typically, they were 1:2 to 1:4 for
epithelial and endothelial cells and 1:2 to 1:250 for fibroblasts. At
most passages, aliquots of the infected cultures were withdrawn for
storage in liquid nitrogen, initiating the next passage, or extracting
infected-cell DNA by using a FlexiGene kit (Qiagen). Following
isolation, strain VR1814 was subjected to CP a further 154 times (i.e.
a total of 214 times) in fibroblasts and 199 times in endothelial cells,
and material from certain passages was retained.
DNA sequencing. The HCMV genome present in infected-cell DNA
at each final passage was sequenced in its entirety by a PCR-based
approach involving the use of a large library of conserved, HCMV-
specific primers for generating and sequencing a set of overlapping
PCR products (Cunningham et al., 2010). Data were obtained in the
form of sequence traces from an Applied Biosystems 3730 instrument
at the BHF Glasgow Cardiovascular Research Centre (University of
Glasgow, UK). The processed data were assembled by using the
Staden Pregap4 and Gap4 programs, and the traces were inspected
visually throughout. Most PCR products were sequenced directly, but
some were cloned into four to six plasmids. In some instances, clones
were utilized to determine whether closely located mutations were
present in the same genome population. Targeted sequencing or PCR
(for deletions) of HCMV DNA in selected lower passages or the
clinical specimen was also carried out.
Production of HCMV stocks. Infected cells at passages in which
RL13
+UL128L
+, RL13
2UL128L
+ or RL13
2UL128L
2 viruses were
predominant were recovered from liquid nitrogen and seeded on
monolayers of the same cell line. Infectivity was amplified by several
rounds of co-culture with uninfected cells and, in the case of
RL13
+UL128L
+ and RL13
2UL128L
+ viruses, by a final 1:1
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harvested as cell-free virus from at least two 175 cm
2 flasks when
complete CPE was achieved. In the case of RL13
+UL128L
+ and
RL13
2UL128L
+ viruses, low-titre CRV was concentrated 100-fold by
centrifugation at 26000 g for 1h at 18 uC.
Infectivity of HCMV stocks. Titrations of cell-free virus were
performed simultaneously in fibroblasts either in 30 mm plates or on
glass coverslips. The cultures on 30 mm plates were fixed and stained
for plaque counting at 12 days p.i. Those on coverslips were fixed at
3 days p.i. and permeabilized for IF analysis. The coverslips were
treated with a mixture of antibodies recognizing the immediate-early
UL123/UL122 proteins (IE1/IE2) (kindly provided by Edward
Mocarski, Jr, Emory University School of Medicine, Atlanta, GA,
USA) labelled using fluorescein isothiocyanate (FITC), and FITC-pre-
conjugated antibody CCH2 (DAKO) recognizing the early UL44
protein (DNA polymerase processivity factor).
The ability of strain VR1814 at various passages in fibroblasts or
endothelial cells to transfer by co-culture to leukocytes (leukocyte
transfer) or endothelial cells (endotheliotropism) was monitored by
using published methods (Gerna et al., 2000, 2002a; Hahn et al.,
2004). Leukocyte transfer was determined by IF detection in
leukocytes of the UL82 protein (pp65; expressed as the number of
positive cells per 2610
5 leukocytes) via a cytospin preparation, and
endotheliotropism was assessed from cell-free virus-induced CPE,
with infection of 80–100% of cells being scored as positive.
Kinetics of virus growth. The passages used were: AF1Rp38
(RL13
+UL128L
+), AF1Ep50 (RL13
2UL128L
+) and AF1Fp60
(RL13
2UL128L
2); U8Rp39 (RL13
+UL128L
+), U8Ep51 (RL13
2
UL128L
+) and U8Fp54 (RL13
2UL128L
2); and U11Rp27 (RL13
+
UL128L
+), U11Rp37 (RL13
2UL128L
+) and U11Fp51 (RL13
2
UL128L
2). For each virus stock, one 35 mm plate containing
2610
5 fibroblasts was infected with 1 infectious unit of virus per
cell (determined from IF titres). After adsorption for 1 h at 37 uC,
unbound virus was removed by washing with medium and the cells
were overlaid with 2 ml medium. Aliquots (1 ml) of medium were
removed for titration of CRV in fibroblasts. Cells in these aliquots
that had detached from the monolayer were pelleted by centrifugation
at 500 g for 10 min at 18 uC and returned to the infected culture in
1 ml fresh medium. Virus yields were stored at 270 uC. At 8 days
p.i., CAV was harvested by scraping the cells into 2 ml fresh medium
and subjecting them to ultrasonic disruption.
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